Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
about
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsInsulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesEfficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitusExenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analysesExenatide Use in the Management of Type 2 Diabetes Mellitus.Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysisSelecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatideIndirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammationEmerging role of GLP-1 receptor agonists in the treatment of obesity.Diabetes: glycaemic control in type 2 (drug treatments).Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Determining predictors of early response to exenatide in patients with type 2 diabetes mellitusGlucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-AnalysisThe role of incretin therapy at different stages of diabetes.Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trialsEfficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisEfficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trialsA review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes.Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysisAddition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapyEffects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureasTreatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.Evolution of exenatide as a diabetes therapeutic.Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.Glucagon-like peptide-1 analogues: An overview.Hypoglycemia: The neglected complicationImportance of achieving the composite endpoints in diabetes.A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.Liraglutide for type 2 diabetes mellitus.Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.The design of the liraglutide clinical trial programme.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
P2860
Q26749495-4E6C8F77-8996-419A-998E-324DC8DA1CA7Q26861313-F57A3510-D3A8-4541-8AA9-E70690054F7EQ28088578-4F01FE44-25B2-43A2-AA83-D4CD88965D71Q30558739-5D7B9C26-57ED-4E5B-9940-E29CEB96D319Q31066859-ABEB7CCA-DE70-4D42-A5C1-A5E37C4C1D14Q33585766-923F79BD-560E-4479-9027-D1DCA875214DQ33664114-99E3A76E-941D-4545-86B0-66DB0D2EF24FQ33767049-0758BDE8-0105-4B32-B89E-DB4E57D5A405Q34133324-C5623176-6C89-43C5-B84A-E86DB45086D8Q34368524-1D520D85-800F-449C-A362-8C7F4CB66C0BQ34405101-94340032-968D-4D1F-8C6A-D5D98FCA561AQ34620465-86E60E0A-4721-4265-80C8-2F5677B68263Q34829290-3E0237E2-BD99-4120-AF00-0DDE1530E939Q35044151-7B4780A9-A923-498D-A7DC-B58D4A9F4923Q35061423-61AB889A-99FC-4EAC-A55C-2CB52BCCE6C6Q35136457-AFB35520-6AE7-4444-BF3A-8A6250428509Q35210164-90BAE6CA-22DE-4753-91C0-E1D709BA8422Q35223375-DEB02743-C038-4C4E-A6DE-76D410AC2F8CQ35677315-177B5011-2BFF-4E68-BEDF-3F4F64720C9CQ35760288-7DCD0AEB-9A5D-4F87-B682-3A5F8C239320Q35780935-115C2D66-9381-403F-B398-D900470EC736Q36011993-2AD4E38E-DD29-4322-A17A-D98BD91F1843Q36071183-82D70189-626A-481B-9E77-A73F59E35663Q36428082-F20DDC47-FF19-4B83-88E1-A71937F2828CQ36520655-AA8D4B28-5E31-494C-8E99-BCD17EDA19A4Q36546914-0E91A923-E0E7-44CD-9425-339EF6E0BEFDQ36584204-64A969C9-968F-4E50-A75F-91D3CFAA9B7EQ36782811-012DB7C6-1BE8-41B9-AB49-F94F7259F61BQ36833164-86825660-957D-4A4A-A1FE-029374CB2AF8Q36877205-B8858F9F-881B-45F8-93AF-16E125954C6AQ36974088-4624C60A-D39D-4546-AC78-FA5BB99FE1FDQ37015969-CCEF55CF-6505-4483-A2CF-CD8D5DA2A2E7Q37201653-D0742B1B-690E-47E7-A8DF-6E259CAA2871Q37201658-89C6C4B3-FC3A-4A2D-A57A-11F32B9BA0B7Q37610459-24170771-97A6-435B-896F-54DE483AAFCDQ37874613-75E29304-B31F-426A-9D39-8CA193E6C064Q37886276-AB29D90C-6FA7-4225-8FD8-C798A61A6879Q37888723-ED0F6EB1-9F75-48E5-9ABF-4D7F306A18E8Q37992253-4D470771-4A2A-4671-85E7-307CFCF323E7Q37995760-5052D522-C8EF-41EC-AD6E-49AC12A07483
P2860
Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Exenatide compared with long-a ...... -Acting insulin (HEELA) study.
@ast
Exenatide compared with long-a ...... -Acting insulin (HEELA) study.
@en
type
label
Exenatide compared with long-a ...... -Acting insulin (HEELA) study.
@ast
Exenatide compared with long-a ...... -Acting insulin (HEELA) study.
@en
prefLabel
Exenatide compared with long-a ...... -Acting insulin (HEELA) study.
@ast
Exenatide compared with long-a ...... -Acting insulin (HEELA) study.
@en
P2093
P2860
P921
P1476
Exenatide compared with long-a ...... -Acting insulin (HEELA) study.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2009.01154.X
P577
2009-12-01T00:00:00Z